TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes
Doctors found that certain tumor markers might help choose the best cancer treatment plan for some patients
A randomized trial compared TAC to ddAC in early breast cancer. The authors observed improved relapse-free survival in specific tumor subtyp…
This study looked at how two different drug schedules worked for people with early breast cancer. Results suggest that specific tumor featur…
Case report details treatment of ANCA-associated vasculitis with Evans syndrome and cerebral infarction in a 72-year-old woman
Treatment stabilized some symptoms but not others in a single patient case
This case report describes a 72-year-old female with ANCA-associated vasculitis, Evans syndrome, and cerebral infarction treated with cortic…
A 72-year-old woman with complex blood vessel disease saw some health markers improve while others remained poor after specific treatments.
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Marburg MS case shows treatment challenges and fatal outcome
A Rare MS Variant Defied Treatment Until This Switch
A 46-year-old woman with aggressive Marburg MS faced treatment-limiting toxicity and died despite multiple therapies, highlighting urgent ca…
A woman with a rare, aggressive form of multiple sclerosis tried many treatments without success, and doctors tried a new approach too late.
Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
Genetic marker may lower risk of cyclophosphamide toxicity in lupus patients
This meta-analysis of 5 observational studies found that the CYP2C19*2 genetic polymorphism is associated with a protective effect against…
A genetic variant linked to lower risk of cyclophosphamide side effects in lupus patients, though evidence remains limited by small study si…
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction
SLE Can Shut Down the Gut — But It Might Be Reversible
This review synthesized 43 cases of SLE-associated intestinal pseudo-obstruction.
Lupus can paralyze the gut without a blockage, but early treatment with immunosuppressives often reverses this dangerous complication.
Nailfold videocapillaroscopy patterns associate with interstitial lung disease and skin fibrosis in systemic sclerosis patients
Does the tiny pattern in your nailbeds predict serious lung scarring in scleroderma?
This prospective cross-sectional study evaluated 70 patients with systemic sclerosis to assess associations between nailfold videocapillaros…
Tiny changes under fingernails can warn of serious lung scarring in scleroderma patients, linking nail patterns to disease severity and qual…
RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death
Rare Blood Cancer Causes Fast Kidney Failure
This case report and literature review describes a 75-year-old female with Waldenström macroglobulinemia and AL lambda-type amyloid nephropa…
When a rare blood cancer attacks the kidneys, standard treatments often fail to stop the fast progression to organ failure.